Product
23-valent pneumococcal polysaccharide vaccine
5 clinical trials
10 indications
Indication
Multiple SclerosisIndication
pneumococcal diseaseIndication
Pneumococcal VaccinesIndication
Immune suppressionIndication
PneumoniaIndication
Rheumatoid ArthritisIndication
Systemic LupusIndication
Sjögren's syndromeIndication
VasculitisIndication
Ankylosing spondylitisClinical trial
An Open-label, Single Arm, Multi-center Extension Study Evaluating Long-term Safety, Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple SclerosisStatus: Recruiting, Estimated PCD: 2027-12-30
Clinical trial
A Randomized, Blinded, Parallel Controlled Phase 3 Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People Aged 2 Years and AboveStatus: Recruiting, Estimated PCD: 2024-03-08
Clinical trial
Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly VeteransStatus: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Randomized, Blind, Parallel Controlled Phase I Clinical Trial to Evaluate the Safety and Preliminary Immunogenicity of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Population Aged 2 Years and OlderStatus: Completed, Estimated PCD: 2021-04-06
Clinical trial
Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response.Status: Completed, Estimated PCD: 2018-09-03